Innovating the RNA Landscape: A Case Study Of The NSW RNA Pilot Manufacturing Facility
In an era of rapid advancements in medical technology, the journey to propel RNA therapeutics to the forefront of healthcare solutions is a testament to collaborative innovation.
The NSW Government and the NSW RNA Bioscience Alliance have committed AU$ 96 million to build the RNA pilot facility and an additional AU$ 119 million for operating costs until 2035.
The new facility will conduct small-scale production of messenger RNA (mRNA), synthetic RNA (sRNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.
Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.
